Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for <i>EGFR</i> Mutations in Lung Cancer
Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The epidermal growth factor receptor (EGFR) mutation is a widely prevalent oncogene driver in non–small cell lung cancer (NSCLC) in East Asia. The detection of EGFR mutations is a standard biomarker test performed routinely in patients with NSCLC for the selection of targeted therapy. Here, our objective was to develop a portable new technique for detecting EGFR (19Del, T790M, and L858R) mutations based on Nanopore sequencing. Materials and Methods The assay employed a blocker displacement amplification (BDA)–based polymerase chain reaction (PCR) technique combined with Nanopore sequencing to detect EGFR mutations. Mutant and wild-type EGFR clones were generated from DNA from H1650 (19Del heterozygous) and H1975 (T790M and L858R heterozygous) lung cancer cell lines. Then, they were mixed to assess the performance of this technique for detecting low variant allele frequencies (VAFs). Subsequently, formalin-fixed, paraffin-embedded (FFPE) tissue and cell-free DNA (cfDNA) from patients with NSCLC were used for clinical validation. Results The assay can detect low VAF at 0.5% mutant mixed in wild-type EGFR. Using FFPE DNA, the concordance rates of EGFR 19Del, T790M, and L858R mutations between our method and Cobas real-time PCR were 98.46%, 100%, and 100%, respectively. For cfDNA, the concordance rates of EGFR 19Del, T790M, and L858R mutations between our method and droplet digital PCR were 94.74%, 100%, and 100%, respectively. Conclusion The BDA amplicon Nanopore sequencing is a highly accurate and sensitive method for the detection of EGFR mutations in clinical specimens.
Abstract
Purpose The epidermal growth factor receptor (EGFR) mutation is a widely prevalent oncogene driver in non–small cell lung cancer (NSCLC) in East Asia. The detection of EGFR mutations is a standard biomarker test performed routinely in patients with NSCLC for the selection of targeted therapy. Here, our objective was to develop a portable new technique for detecting EGFR (19Del, T790M, and L858R) mutations based on Nanopore sequencing. Materials and Methods The assay employed a blocker displacement amplification (BDA)–based polymerase chain reaction (PCR) technique combined with Nanopore sequencing to detect EGFR mutations. Mutant and wild-type EGFR clones were generated from DNA from H1650 (19Del heterozygous) and H1975 (T790M and L858R heterozygous) lung cancer cell lines. Then, they were mixed to assess the performance of this technique for detecting low variant allele frequencies (VAFs). Subsequently, formalin-fixed, paraffin-embedded (FFPE) tissue and cell-free DNA (cfDNA) from patients with NSCLC were used for clinical validation. Results The assay can detect low VAF at 0.5% mutant mixed in wild-type EGFR. Using FFPE DNA, the concordance rates of EGFR 19Del, T790M, and L858R mutations between our method and Cobas real-time PCR were 98.46%, 100%, and 100%, respectively. For cfDNA, the concordance rates of EGFR 19Del, T790M, and L858R mutations between our method and droplet digital PCR were 94.74%, 100%, and 100%, respectively. Conclusion The BDA amplicon Nanopore sequencing is a highly accurate and sensitive method for the detection of EGFR mutations in clinical specimens.
참고문헌 (24)
- Hirsch FR, "Epidermal growth factor receptor in non-small-cell lung carcinomas : correlation between gene copy number and protein expression and impact on prognosis", J Clin Oncol, 21, pp.3798~3807 (2003)
- Miller VA, "Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer", J Clin Oncol, 22, pp.1103~1109 (2004)
- Gupta R, "Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma : the need to test neoplasms with more than one method", Mod Pathol, 22, pp.128~133 (2009)
- Riely GJ, "Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib", Clin Cancer Res, 12, pp.839~844 (2006)
- Bethune G, "Epidermal growth factor receptor(EGFR)in lung cancer : an overview and update", J Thorac Dis, 2, pp.48~51 (2010)
- Deepak S, "Real-time PCR : revolutionizing detection and expression analysis of genes", Curr Genomics, 8, pp.234~251 (2007)
- Pinheiro LB, "Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification", Anal Chem, 84, pp.1003~1011 (2012)
- Guha M, "DISSECT method using PNA-LNA clamp improves detection of EGFR T790m mutation", PLoS One, 8, pp.e67782~ (2013)
- Yao J, "Blocker displacement amplification mediated PCR based screen-printed carbon electrode biosensor and lateral flow strip strategy for CYP2C19*2 genotyping", Biosens Bioelectron, 207, pp.114138~ (2022)
- Smith GD, "Allele-specific PCR with competitive probe blocking for sensitive and specific detection of BRAF V600E in thyroid fine-needle aspiration specimens", Acta Cytol, 55, pp.576~583 (2011)
- Pellestor F, "The peptide nucleic acids(PNAs), powerful tools for molecular genetics and cytogenetics", Eur J Hum Genet, 12, pp.694~700 (2004)
- Latorra D, "Enhanced allele-specific PCR discrimination in SNP genotyping using 3’ locked nucleic acid(LNA)primers", Hum Mutat, 22, pp.79~85 (2003)
- Xu J, "PEAC : an ultrasensitive and cost-effective MRD detection system in non-small cell lung cancer using plasma specimen", Front Med(Lausanne), 9, pp.822200~ (2022)
- Thirunavukarasu D, "Oncogene concatenated enriched amplicon Nanopore sequencing for rapid, accurate, and affordable somatic mutation detection", Genome Biol, 22, pp.227~ (2021)
- Wang Y, "Nanopore sequencing technology, bioinformatics and applications", Nat Biotechnol, 39, pp.1348~1365 (2021)
- Norris AL, "Nanopore sequencing detects structural variants in cancer", Cancer Biol Ther, 17, pp.246~253 (2016)
- Mimosa ML, "A novel approach to detect IDH point mutations in gliomas using Nanopore sequencing : test validation for the clinical laboratory", J Mol Diagn, 25, pp.133~142 (2023)
- Pierson-Perry JF, "Evaluation of detection capability for clinical laboratory measurement procedures; approved guideline (EP17-A2)", Clinical Laboratory Standards Institute, ~ (2012)
- Lopez-Rios F, "Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer", J Clin Pathol, 66, pp.381~385 (2013)
- Kebschull JM, "Sources of PCR-induced distortions in high-throughput sequencing data sets", Nucleic Acids Res, 43, pp.e143~ (2015)
- Malapelle U, "Profile of the Roche cobas(R)EGFR mutation test v2 for non-small cell lung cancer", Expert Rev Mol Diagn, 17, pp.209~215 (2017)
- Wei Z, "Patients harboring epidermal growth factor receptor(EGFR)double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors", Thorac Cancer, 5, pp.126~132 (2014)
- Harrison PT, "Rare epidermal growth factor receptor(EGFR)mutations in non-small cell lung cancer", Semin Cancer Biol, 61, pp.167~179 (2020)
- Liang H, "Concomitant mutations in EGFR 19Del", L858R mutation and their association with response to EGFR-TKIs in NSCLC patients, 2020, pp.12, 8653~8662